Urology
Volume 68, Issue 6 , Pages 1145-1151 , December 2006

Genetic susceptibility and oxidative stress in prostate cancer: Integrated model with implications for prevention

  • Eric A. Klein

      Affiliations

    • Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic Foundation, Cleveland, Ohio
    • Taussing Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio
    • Cleveland Clinic Lerner College of Medicine, Cleveland Clinic Foundation, Cleveland, Ohio
    • Corresponding Author InformationReprint requests: Eric A. Klein, M.D., Section of Urologic Oncology, Glickman Urological Institute, Cleveland Clinic Foundation, Desk A100, 9500 Euclid Avenue, Cleveland, OH 44122.
    • ,
  • Graham Casey

      Affiliations

    • Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio
    • Taussing Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio
    • Cleveland Clinic Lerner College of Medicine, Cleveland Clinic Foundation, Cleveland, Ohio
    • ,
  • Robert Silverman

      Affiliations

    • Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, Ohio
    • Taussing Cancer Center, Cleveland Clinic Foundation, Cleveland, Ohio
    • Cleveland Clinic Lerner College of Medicine, Cleveland Clinic Foundation, Cleveland, Ohio

Received 22 November 2005 ,Accepted 15 August 2006.

References 

  1. Eeles RA, Dearnaley DP, Ardern-Jones A, et al. Familial prostate cancer: the evidence and the Cancer Research Campaign/British Prostate Group (CRC/BPG) UK Familial Prostate Cancer Study. Br J Urol. 1997;79(suppl 1):8–14
  2. Ahlbom A, Lichtenstein P, Malmstrom H, et al. Cancer in twins: genetic and nongenetic familial risk factors. J Natl Cancer Inst. 1994;89:287–293
  3. Bratt O. Hereditary prostate cancer: clinical aspects. J Urol. 2002;168:906–913
  4. Carter BS, Bova GS, Beaty TH, et al. Hereditary prostate cancer: epidemiologic and clinical features. J Urol. 1993;150:797–802
  5. Gillanders EM, Xu J, Chang BL, et al. Combined genome-wide scan for prostate cancer susceptibility genes. J Natl Cancer Inst. 2004;96:1240–1247
  6. Carpten J, Nupponen N, Isaacs S, et al. Germline mutations in the ribonuclease L (RNase L) gene in hereditary prostate cancer 1 (HPC1)-linked families. Nat Genet. 2002;30:181–184
  7. Tavtigian SV, Simard J, Teng DH, et al. A candidate prostate cancer susceptibility gene at chromosome 17p. Nat Genet. 2001;27:172–180
  8. Xu J, Zheng SL, Komiya A, et al. Germline mutations and sequence variants of the macrophage scavenger receptor 1 gene are associated with prostate cancer risk. Nat Genet. 2002;32:321–325
  9. Dong X, Wang L, Taniguchi K, et al. Mutations in CHEK2 associated with prostate cancer risk. Am J Hum Genet. 2003;72:270–280
  10. Edwards SM, Kote-Jarai Z, Meitz J, et al. Two percent of men with early-onset prostate cancer harbor germline mutations in the BRCA2 gene. Am J Hum Genet. 2003;72:1–12
  11. Marchesani M, Hakkarainen A, Tuomainen TP, et al. New paraoxonase 1 polymorphism I102V and the risk of prostate cancer in Finnish men. J Natl Cancer Inst. 2003;95:812–818
  12. Xu J, Zheng SL, Turner A, et al. Associations between hOGG1 sequence variants and prostate cancer susceptibility. Cancer Res. 2002;62:2253–2257
  13. Lindmark F, Zheng SL, Wiklund F, et al. H6D polymorphism in macrophage-inhibitory cytokine-1 gene associated with prostate cancer. J Natl Cancer Inst. 2004;96:1248–1254
  14. Zheng SL, Augustsson-Balter K, Chang B, et al. Sequence variants of Toll-like receptor 4 are associated with prostate cancer risk: results from the Cancer Prostate in Sweden Study. Cancer Res. 2004;64:2918–2922
  15. Berthon P, Valeri A, Cohen-Akenine A, et al. Predisposing gene for early-onset prostate cancer, located on chromosome 1q42.2-43. Am J Hum Genet. 1998;62:1416–1420
  16. Gibbs M, Stanford JL, McIndoe RA, et al. Evidence for a rare prostate cancer susceptibility locus at chromosome 1p36. Am J Hum Genet. 1999;64:776–780
  17. Xu J, Meyers D, Freije D, et al. Evidence for a prostate cancer susceptibility locus on the X chromosome. Nat Genet. 1998;20:175–178
  18. Smith JR, Freije D, Carpten JD, et al. Major susceptibility locus for prostate cancer on chromosome 1 suggested by a genome-wide search. Science. 1996;274:1371–1374
  19. Eeles RA, Durocher F, Edwards S, et al. Linkage analysis of chromosome 1q markers in 136 prostate cancer families. Am J Hum Genet. 1998;62:653–658
  20. Silverman RH. Implications for RNase L in prostate cancer biology. Biochemistry. 2003;42:1805–1812
  21. Xiang Y, Wang Z, Murakami J, et al. Effects of RNaseL mutations associated with prostate cancer on apoptosis induced by 2′,5′-oligoadenylates. Cancer Res. 2003;63:6795–6801
  22. Casey G, Neville PJ, Plummer SJ, et al. RNASEL Arg462Gln variant is implicated in up to 13% of prostate cancer cases. Nat Genet. 2002;32:581–583
  23. Rennert H, Zeigler-Johnson CM, Addya K, et al. Association of susceptibility alleles in ELAC2/HPC2, RNASEL/HPC1, and MSR1 with prostate cancer severity in European American and African American men. Cancer Epidemiol Biomarkers Prev. 2005;14:949–957
  24. Maier C, Haeusler J, Herkommer K, et al. Mutation screening and association study of RNASEL as a prostate cancer susceptibility gene. Br J Cancer. 2005;92:1159–1164
  25. Wiklund F, Jonsson BA, Brookes AJ, et al. Genetic analysis of the RNASEL gene in hereditary, familial, and sporadic prostate cancer. Clin Cancer Res. 2004;10:7150–7156
  26. Malathi K, Paranjape JM, Ganapathi R, et al. HPC1/RNASEL mediates apoptosis of prostate cancer cells treated with 2′,5′-oligoadenylates, topoisomerase I inhibitors, and tumor necrosis factor-related apoptosis-inducing ligand. Cancer Res. 2004;64:9144–9151
  27. Goode EL, Stanford JL, Peters MA, et al. Clinical characteristics of prostate cancer in an analysis of linkage to four putative susceptibility loci. Clin Cancer Res. 2001;7:2739–2749
  28. Gronberg H, Isaacs SD, Smith JR, et al. Characteristics of prostate cancer in families potentially linked to the hereditary prostate cancer 1 (HPC1) locus. JAMA. 1997;278:1251–1254
  29. Platt N, Gordon S. Is the class A macrophage scavenger receptor (SR-A) multifunctional? (The mouse’s tale). J Clin Invest. 2001;108:649–654
  30. Thomas CA, Li Y, Kodama T, et al. Protection from lethal gram-positive infection by macrophage scavenger receptor-dependent phagocytosis. J Exp Med. 2000;191:147–156
  31. Lemaitre B, Nicolas E, Michaut L, et al. The dorsoventral regulatory gene cassette spatzle/Toll/cactus controls the potent antifungal response in Drosophila adults. Cell. 1996;86:973–983
  32. O’Neill LA, Fitzgerald KA, Bowie AG. The Toll-IL-1 receptor adaptor family grows to five members. Trends Immunol. 2003;24:286–290
  33. Shih DM, Gu L, Xia YR, et al. Mice lacking serum paraoxonase are susceptible to organophosphate toxicity and atherosclerosis. Nature. 1998;394:284–287
  34. De Winther MP, Gijbels MJ, Van Dijk KW, et al. Transgenic mouse models to study the role of the macrophage scavenger receptor class A in atherosclerosis. Int J Tissue React. 2000;22:85–91
  35. Boiteux S, Radicella JP. The human OGG1 gene: structure, functions, and its implication in the process of carcinogenesis. Arch Biochem Biophys. 2000;377:1–8
  36. Coussens LM, Werb Z. Inflammation and cancer. Nature. 2002;420:860–867
  37. Platz EA, De Marzo AM. Epidemiology of inflammation and prostate cancer. J Urol. 2004;171:S36–S40
  38. U.S. Department of Health and Human Services, Public Health Service, National Toxicology Program: 11th Report on Carcinogens, 2005. Available at: http://ntp.niehs.nih.gov/ntp/roc/toc11.html. Accessed June 6, 2005.
  39. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;349:366–381
  40. Dennis LK, Dawson DV. Meta-analysis of measures of sexual activity and prostate cancer. Epidemiology. 2002;13:72–79
  41. Dennis LK, Lynch CF, Torner JC. Epidemiologic association between prostatitis and prostate cancer. Urology. 2002;60:78–83
  42. Samanta M, Harkins L, Klemm K, et al. High prevalence of human cytomegalovirus in prostatic intraepithelial neoplasia and prostatic carcinoma. J Urol. 2003;170:998–1002
  43. Zambrano A, Kalantari M, Simoneau A, et al. Detection of human polyomaviruses and papillomaviruses in prostatic tissue reveals the prostate as a habitat for multiple viral infections. Prostate. 2002;53:263–276
  44. De Marzo AM, Marchi VL, Epstein JI, et al. Proliferative inflammatory atrophy of the prostate: implications for prostatic carcinogenesis. Am J Pathol. 1999;155:1985–1992
  45. Putzi MJ, De Marzo AM. Morphologic transitions between proliferative inflammatory atrophy and high-grade prostatic intraepithelial neoplasia. Urology. 2000;56:828–832
  46. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med. 2003;349:366–381
  47. Kumar-Sinha C, Shah RB, Laxman B, et al. Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer. Am J Pathol. 2004;164:787–793
  48. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med. 2003;349:215–224
  49. Andriole GL, Roehrborn C, Schulman C, et al. Effect of dutasteride on the detection of prostate cancer in men with benign prostatic hyperplasia. Urology. 2004;64:537–541
  50. Villa LL, Costa RL, Petta CA, et al. Prophylactic quadrivalent human papillomavirus (types 6, 11, 16, and 18) L1 virus-like particle vaccine in young women: a randomised double-blind placebo-controlled multicentre phase II efficacy trial. Lancet Oncol. 2005;6:271–278

PII: S0090-4295(06)02069-3

doi: 10.1016/j.urology.2006.08.1074

Urology
Volume 68, Issue 6 , Pages 1145-1151 , December 2006

Article Tools

* Image Usage & Resolution